Evaluation of Pharmacodynamic Effects of Intratumoral Delivery of Plasmid IL-12 Electroporation in Patients With Triple Negative Breast Cancer

Trial Profile

Evaluation of Pharmacodynamic Effects of Intratumoral Delivery of Plasmid IL-12 Electroporation in Patients With Triple Negative Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2018

At a glance

  • Drugs Tavokinogene telsaplasmid (Primary)
  • Indications Advanced breast cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Sponsors OncoSec Medical
  • Most Recent Events

    • 17 Jul 2018 According to an OncoSec Medical media release, the study has reached its target enrollment of 10 patients.
    • 28 Jun 2018 According to an OncoSec Medical media release, the company expects to complete patient enrolment and provide top-line data from this trial in the second half of 2018.
    • 13 Jun 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top